SCHEMBL19481678

SCHEMBL19481678

O=C(C1CC1)N1CCN(c2ccnn3cc(-c4ccc(C5CCNCC5)cc4)cc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RET P07949 4/20 0.41
ALDH1A1 P00352 1/20 0.40
KHK P50053 1/20 0.40
ACVR1 Q04771 3/20 0.39
BMPR1B O00238 2/20 0.39
BMPR1A P36894 2/20 0.39
ACVR1B P36896 2/20 0.39
ACVRL1 P37023 2/20 0.39
IDE P14735 1/20 0.39
MAPK1 P28482 1/20 0.38
PIK3CD O00329 1/20 0.38
PIK3CB P42338 1/20 0.38
RUVBL1 Q9Y265 1/20 0.37
TLR9 Q9NR96 4/20 0.37
TLR8 Q9NR97 4/20 0.37
TLR7 Q9NYK1 4/20 0.37
KIT P10721 1/20 0.37
TP53 P04637 1/20 0.36
CYP46A1 Q9Y6A2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19481672 0.94 JAK1 (0.40) RETALDH1A1KHKACVR1BMPR1B
SCHEMBL19481662 0.91 ALDH1A1 (0.41) RETALDH1A1IDEMAPK1PIK3CD
SCHEMBL19481680 0.90 JAK1 (0.43) RETALDH1A1KHKIDEMAPK1
SCHEMBL19481683 0.90 RET (0.41) RETALDH1A1IDEMAPK1RUVBL1
SCHEMBL19481787 0.88 ALDH1A1 (0.40) RETALDH1A1IDEMAPK1KIT
SCHEMBL19458948 0.88 TDP1 (0.45) RETALDH1A1KHKACVR1BMPR1B
SCHEMBL19482305 0.87 ALDH1A1 (0.38) RETALDH1A1IDEMAPK1RUVBL1
SCHEMBL19481705 0.86 KIT (0.41) RETALDH1A1KHKIDEMAPK1
SCHEMBL19481784 0.86 TLR9 (0.41) RETALDH1A1IDEMAPK1TLR9
SCHEMBL19481764 0.86 ALDH1A1 (0.39) RETALDH1A1IDEMAPK1KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 RET 50/4885ALDH1A1 3277/4885KHK 2037/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 RET 50/4885ALDH1A1 3277/4885KHK 2037/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 RET 50/4885ALDH1A1 3277/4885KHK 2037/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 RET 56/4885ALDH1A1 2488/4885KHK 2328/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 RET 50/4885ALDH1A1 3277/4885KHK 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.